Peginterferon alfa-2a (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Preliminary report of a randomized study.

被引：5
|
作者：
Petrolati, A
Lionetti, R
Donato, F
Merli, M
Burra, P
Angeli, P
Strazzabosco, M
Tisone, G
Angelico, M
机构：
[1] Univ Roma Tor Vergata, Liver Transplantat Unit, Rome, Italy
[2] Univ Milan, Liver Transplantat Unit, Milan, Italy
[3] Univ Roma La Sapienza, Liver Transplantat Unit, Rome, Italy
[4] Univ Padua, Liver Transplantat Unit, Padua, Italy
[5] Univ Bergamo, Liver Transplantat Unit, Bergamo, Italy
来源：
JOURNAL OF HEPATOLOGY | 2004年 / 40卷
关键词：
D O I：
10.1016/S0168-8278(04)90100-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
100
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [1] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [2] Peginterferon alfa-2a (40KD) as prophylaxis and treatment for recurrent hepatitis C virus (HCV) infection after orthotopic liver transplantation (OLT)
    Chalasani, N
    Manzarbeitia, C
    Ferenci, P
    Vogel, W
    Fontana, R
    Voigt, M
    Riely, C
    Martin, P
    Teperman, LW
    Sidhu, R
    Jaio, J
    Lopez-Talavera, JC
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A664 - A664
  • [3] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [4] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    [J]. ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [5] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [6] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [7] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    [J]. HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [8] Peginterferon alfa-2a (40KD): A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C
    Modi, MW
    Lamb, MW
    Shiomi, M
    [J]. POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS, 2003, 519 : 59 - 67
  • [9] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
    Bruno, Savino
    Shiffman, Mitchell L.
    Roberts, Stuart K.
    Gane, Edward J.
    Messinger, Diethelm
    Hadziyannis, Stephanos J.
    Marcellin, Patrick
    [J]. HEPATOLOGY, 2010, 51 (02) : 388 - 397
  • [10] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    [J]. HEPATOLOGY, 2003, 38 (04) : 244A - 245A
12345